Medications are a key component of disease management in pediatric patients with sickle cell disease (SCD). More specifically, hydroxyurea, prophylactic penicillin, and iron chelators are commonly prescribed as daily medications (Ware de Montalembert, Tshilolo, & Abboud, 2017). Despite their role in preventing and treating symptoms, past studies indicate suboptimal adherence rates ranging between 55% and 74% (Loiselle, Lee, Szulczewski, Drake, Crosby, & Pai, 2015). As such, attention to strategies to increase adherence and ultimately improve health outcomes for children with SCD is of value. To this end, Shih and Cohen conducted a rigorous systematic review of psychological interventions designed to enhance medication adherence among pediatric patients with SCD. They identified just nine intervention studies that met eligibility criteria for inclusion in their review during the nearly 50-year time span of 1970–2018 (Shih & Cohen, 2020). This stands in sharp contrast to the volume of adherence intervention studies in other pediatric groups, where far more intervention trials have been published. For example, a recent review of adherence-focused interventions for pediatric diabetes included 24 studies over a 29-year review period (Aljawarneh, Al-Qaissi, & Ghunaim, 2020). Similarly, in pediatric asthma 79 studies over a 19-year review period were reviewed (Gray, Netz, McConville, Fedele, Wagoner, & Schaefer, 2018).